Jove
Visualize
Contact Us

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type 1 diabetes pathogenesis is modulated by spontaneous autoimmune responses to endogenous retrovirus antigens in NOD mice.

European journal of immunology·2017
Same author

Specificities of broadly neutralizing anti-HIV-1 sera.

Current opinion in HIV and AIDS·2010
Same author

Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.

Journal of virology·2008
Same author

Identification of a D-amino acid decapeptide HIV-1 entry inhibitor.

Biochemical and biophysical research communications·2006
Same author

The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.

Journal of virology·2004
Same author

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Journal of virology·2003
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 20, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

An HIV vaccine blueprint.

James Binley1

  • 1San Diego Biomedical Research Institute, San Diego, CA, USA.

Science (New York, N.Y.)
|June 18, 2026
PubMed
Summary

Infection with a novel chimeric virus in rhesus macaques revealed a method for developing broadly neutralizing antibodies against viruses. This discovery offers new strategies for vaccine development and therapeutic interventions.

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • Developing broadly neutralizing antibodies (bNAbs) is crucial for effective vaccines against rapidly mutating viruses.
  • Previous attempts to elicit bNAbs have faced challenges due to viral diversity and immune evasion.

Purpose of the Study:

  • To identify a viral challenge that elicits broadly neutralizing antibodies.
  • To understand the mechanisms behind the generation of these antibodies.

Main Methods:

  • Infection of rhesus macaques with a specific chimeric simian-human immunodeficiency virus (SHIV).
  • Longitudinal analysis of antibody responses, viral load, and immune cell populations.
  • Characterization of antibody binding and neutralization breadth.

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Related Experiment Videos

Last Updated: Jun 20, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Main Results:

  • The chimeric virus infection successfully induced potent and broadly neutralizing antibody responses in macaques.
  • Specific viral envelope structures were identified as key targets for these antibodies.
  • The antibody response demonstrated cross-reactivity against a range of viral strains.

Conclusions:

  • Chimeric virus infection provides a viable model for studying bNAb induction.
  • This approach may inform the design of more effective HIV vaccines.
  • Understanding the antibody 'recipe' can guide future immunogen design.